Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (121-130 of 313) with videos related to

Pageof 32
Sort By:
Urology|March 27, 2007
Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injectionHeinrich Schulte-Baukloh, Hans Bigalke, Gert Heine, et al.
World Journal of Urology|March 31, 2012
Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable resultsGunnar Lohm, Dirk Bottke, Basil Jamil, et al.
Urologia Internationalis|March 9, 2012
Selective lymph node dissection for castration-resistant prostate cancerJonas Busch, Stefan Hinz, Carsten Kempkensteffen, et al.
Anticancer Research|July 15, 2009
New markers and multivariate models for prostate cancer detectionCarsten Stephan, Harry Rittenhouse, Henning Cammann, et al.
World Journal of Urology|March 4, 2009
Prognostic value of intraoperative parameters observed during vasectomy reversal for predicting postoperative vas patency and fertilityStefan Hinz, Soroush Rais-Bahrami, Wolf H Weiske, et al.
Clinical Chemistry and Laboratory Medicine|September 26, 2009
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?Carsten Stephan, Thomas Köpke, Axel Semjonow, et al.
Advances in Therapy|January 6, 2017
The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter SettingMargit Pohle, Ahmed Magheli, Tom Fischer, et al.
European Urology|February 2, 2010
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumoursFlorian Jentzmik, Carsten Stephan, Kurt Miller, et al.
European Urology|September 24, 2017
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason ScoreKurt Miller, Joan Carles, Jürgen E Gschwend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implicationsFrank Christoph, Steffen Weikert, Carsten Kempkensteffen, et al.
Pageof 32

Showing results (121-130 of 313) with videos related to

Sort By:
Pageof 32
Urology|March 27, 2007
Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injectionHeinrich Schulte-Baukloh, Hans Bigalke, Gert Heine, et al.
World Journal of Urology|March 31, 2012
Salvage radiotherapy in patients with persistently detectable PSA or PSA rising from an undetectable range after radical prostatectomy gives comparable resultsGunnar Lohm, Dirk Bottke, Basil Jamil, et al.
Urologia Internationalis|March 9, 2012
Selective lymph node dissection for castration-resistant prostate cancerJonas Busch, Stefan Hinz, Carsten Kempkensteffen, et al.
Anticancer Research|July 15, 2009
New markers and multivariate models for prostate cancer detectionCarsten Stephan, Harry Rittenhouse, Henning Cammann, et al.
World Journal of Urology|March 4, 2009
Prognostic value of intraoperative parameters observed during vasectomy reversal for predicting postoperative vas patency and fertilityStefan Hinz, Soroush Rais-Bahrami, Wolf H Weiske, et al.
Clinical Chemistry and Laboratory Medicine|September 26, 2009
Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?Carsten Stephan, Thomas Köpke, Axel Semjonow, et al.
Advances in Therapy|January 6, 2017
The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter SettingMargit Pohle, Ahmed Magheli, Tom Fischer, et al.
European Urology|February 2, 2010
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumoursFlorian Jentzmik, Carsten Stephan, Kurt Miller, et al.
European Urology|September 24, 2017
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason ScoreKurt Miller, Joan Carles, Jürgen E Gschwend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implicationsFrank Christoph, Steffen Weikert, Carsten Kempkensteffen, et al.
Pageof 32